Exhibit 4.2


 





		 

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                           Regulations
                           of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG

                            

                           (Organisationsreglement)


                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                            

                           February
1, 2020

                            

                            

                            

                           




 



	Novartis
    AG
	4002
    Basel, Switzerland
	 
	©
    February 2020, Novartis AG


 






     


    
	 1	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

  


	 	 	Table
    of Contents	 
	 	 	 	 
	Section
    1	 	Scope
    of the Regulations, Organization in general	2
	 	 	 	 
	Section
    2	 	General
    Provisions	2
	 	 	 	 
	Section
    3	 	Meetings
    of the Board, the Board Committees and the Executive Committee	3
	 	 	 	 
	Section
    4	 	Board
    of Directors	4
	 	 	 	 
	Section
    5	 	Executive
    Committee	8
	 	 	 	 
	Section
    6	 	Internal
    Audit	9
	 	 	 	 
	Section
    7	 	Effectiveness,
    Amendments	10
	 	 	 	 
	Appendix
    I	 	Board
    Committees Charter	11
	 	 	 	 
	Appendix
    II	 	Independence
    Criteria for the Board and the Board Committees	23
	 	 	 	 
	 	 	Abbreviations
    and Definitions	26


 


All references
to individuals apply to both male and female persons.


 



     


    
	 2	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    







 


	Section
    1	 	Scope
    of the Regulations, Organization in general
	 	 	 
	 	 	Article
    1
	Scope	 	These
        Regulations govern the internal organization as well as the duties, powers and responsibilities of the following executive
        bodies and persons of the Company:

        –
        Board and its Committees

        –
        Chairman

        –
        Vice-Chairman

        –
        CEO

        –
        Executive Committee (including its sub-committees) and

        –
        Internal Audit

	 	 	 
	 	 	Article
    2
	Company
    Structure	 	The
    Company is a holding company, which directly or indirectly owns a global group of companies that conduct the Business. To
    ensure proper functioning of the Business in the interests of the Company and its shareholders and
    to comply with various requirements imposed by relevant laws and regulatory authorities, the Board shall supervise and, where
    necessary and appropriate, provide overall strategic direction for the Business.
	 	 	 
	Section
    2	 	General
    Provisions
	 	 	 
	 	 	Article
    3
	Duty
    of Care and Loyalty	 	Each
    Director or Executive is under the duty to carry out his/her responsibilities with due care and to safeguard and further the
    interests of the Group, the Company and its shareholders, including the creation of long-term value.
	 	 	 
	 	 	Article
    4
	Conflict
    of Interest	 	Each
        Director or Executive arranges his/her personal and business affairs so as to avoid an actual or apparent Conflict of
        Interest.

         

        No
        Director or Executive shall participate in decisions and resolutions on matters, which affect, or reasonably might affect,
        his/her interests or the interests of a person close to him/her (but he or she may participate in the discussion). If
        the Director or Executive is in a position of a permanent Conflict of Interest or any other non-solvable situation that
        hinders him/her in carrying out his/her duties to the full, he/she shall offer his/her resignation.

         

        Each
Director or Executive must make a notification immediately, if the circumstances change so that it might affect or appear to affect
the Director’s or Executive’s independence. In case of a new mandate, notification must occur prior to accepting such
new mandate.




 






     


    
	 3	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	 	 	Required disclosures include (but are not limited to):









	 	 	(i)	a material change (or contemplated change) of his/her business or professional
        affiliations or responsibilities; and/or
	 	 	(ii)	 any change of circumstances that may affect or appear to affect his/her independence
        or give rise to a Conflict of Interest.
	 	 	 	 
	 	 	Disclosure must be made by:
	 	 	(i)	the
Chairman to the Chairperson of the GNCRC; and by
	 	 	(ii)	
        a Director or the CEO to the Chairman; and by
	 	 	(iii)	an
Executive to the CEO.
	 	 	 	 
	 	 	











The Chairman, the CEO and the Chairperson of the GNCRC, respectively, must review the disclosures and inform the Board, respectively the ECN, with a corresponding proposal for appropriate mitigating measures, if any.



	 	 	 
	 	 	Article 5
	Confidentiality	 	Each Director and Executive keeps at all times strictly confidential all information – except information already in the public domain – relating to the Company and/or the Group, which the member has learned during the exercise of the duties. This obligation and duty continues even after the expiration of the term of office.


 


Documents of the Company and/or the Group must be returned by the Director or Executive at the latest on expiry of the term of office. If required, e.g. in case of legal proceedings, the Director or Executive can access relevant documents at the office of the Corporate Secretary.



	 	 	 
	Section 3	 	Meetings of the Board, the Board Committees and the Executive
    Committee
	 	 	 
	 	 	Article
6


	No
                                         Representation of Members

         
	 	A
    Director or Executive who is not able to participate in a Board, Board Committee or an Executive Committee meeting may not
    be represented by another Director or Executive or any other person.
	 	 	Article
    7
	Quorum,
                                         Majority

        Requirements
	 	Unless
                                         stated otherwise in these Regulations, the presence in person, by telephone, by video
                                         conference or other technical means of a majority of the members is required for any
                                         meeting.

         

        If
the chair does not participate, the meeting will be chaired by the deputy or, in his/her absence, by any member appointed by the
other members as ad hoc chair.

        




 






     


    
	 4	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	 	 	


Resolutions require the affirmative majority of the votes cast. If an item is, however, not on the agenda, resolutions are passed by an affirmative vote of at least two thirds of the Directors or Executives, present at a meeting.


 


In the event of a tie on any issue, (i) in a Board Committee, the full Board decides the issue, and (ii) in the Executive Committee, the CEO decides the issue.



	 	 	 	 
	 	 	Article 8
	Circular
                                         Resolutions

         
	 	A proposal for a circular resolution must be communicated to all members, giving a deadline for responding, and is only deemed to have passed if:






	 	 	(i)	more than two-thirds of all members cast a vote or give written notice
        that they abstain (written notice can include email notice);
	 	 	(ii)	an absolute majority of all members casting a vote approve the proposed
        resolution; and
	 	 	(iii)	no member requests a meeting within the deadline for responding in relation to the
subject matter of the proposed resolution.
	 	 	 	 
	 	 	A circular resolution must be recorded under a separate heading in the minutes of the following meeting.
	 	 	 	 
	 	 	Article 9
	Secretary,
    Minutes	 	The Board and the Board Committees each appoint a secretary, who need not be a member of the body.


 


The secretaries of the Board and the Board Committees, and the General Counsel in case of the Executive Committee, keep the meeting minutes, which contain all resolutions adopted at the meeting and the key decision-making factors.



	 	 	 
	 	 	Article 10
	Application
    to other Bodies	 	Articles 3 – 9 apply analogously to all other management committees of the Company and their members.
	 	 	 
	Section
4	 	Board of Directors
	 	 	 
	 	 	Article 11
	Independence	 	The majority of the Directors have to meet the independence criteria set forth in Appendix II.
	 	 	 
	 	 	Article 12
	Duties
    of the Board	 	The
                                         Board is the ultimate executive body of the Company.
	 	 	 
	 	 	It
        shall resolve all Business matters, which are not reserved to the authority of the General Meeting or to other executive
        bodies of the Company by law, the Articles, or these Regulations.



 






     


    
	 5	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


		 	


In
particular, the Board has the following duties:






	 	 	a)	The
    ultimate direction of the Business, including, without limitation, the taking of resolutions and the giving of instructions
    or overall guidance regarding the following matters (where applicable, the duties of the Board are further defined and specified
    in internal regulations):
	 	 	 	–	The strategy upon
    recommendation of the Executive Committee.
	 	 	 	–	The entry into new
    areas of activity and withdrawal from existing areas of the Business; acquisitions and divestments of companies, participations
    in companies or businesses, or incorporations or liquidations of companies or businesses, if such matters are of fundamental
    significance to the Business.
	 	 	 	–	The
    opening and closing down of sites of fundamental significance to the Business.
	 	 	 	–	The
    initiation and settlement of legal proceedings of funda- mental significance to the Business.
	 	 	 	–	The
    setting of financial targets.
	 	 	 	–	The review and approval
    of corporate policies that are fundamental to the Group, as determined by the Chairman and the CEO.
	 	 	 	–	The adoption from
    time to time of further regulations and instructions regarding the organization of the Business and the duties and responsibilities
    of the executive bodies.
	 	 	b)	The
    determination of the organization of the Company and the Group.
	 	 	c)	The
    manner of governance of the Group.
	 	 	d)	The
    regular review of the Group’s culture.
	 	 	e)	The
    review of the Group’s risk management system and of the most significant risks and how these are managed.
	 	 	f)	The
    determination of the Group’s accounting system, financial controls and financial planning.
	 	 	g)	The
    review and approval of the annual report of the Company and of the Group, incl. the Compensation Report.
	 	 	h)	The
    nomination or appointment, removal, determination of duties and responsibilities, and succession plans of the following persons
    (subject to the powers of the General Meeting):
	 	 	 	–	Vice-Chairman
	 	 	 	–	Board Committee
    members and Chairpersons
	 	 	 	–	CEO
	 	 	 	–	Executives
	 	 	 	–	Independent Proxy
	 	 	 	–	Such other persons
    as the Board may determine, from time to time, as having significant impact on the Business.



 






     


    
	 6	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	 	i)	The
    composition of the Board, including the appropriate skills and experiences to be considered in succession planning.
	 	j)	The
    designation of those persons who have signatory power for the Company and the manner in which such persons may sign on behalf
    of the Company.
	 	k)	The
    ultimate supervision of the persons entrusted with the management of the Business, specifically in view of their compliance
    with laws, the Articles, these Regulations and other applicable regulations, directives and instructions.
	 	l)	The
    preparations for the General Meeting and carrying out the resolutions of the General Meeting, including the preparation of
    the proposals to the General Meeting related to the compensation of the Board and of the Executive Committee and to the Compensation
    Report, as per the Articles.
	 	m)	The
    notification of the court if liabilities exceed assets.
	 	n) 	The
    adoption of resolutions concerning an increase of the share capital to the extent that such power is vested in the Board (article 651
    paragraph 4 CO), as well as resolutions concerning confirmation of capital increases and related amendments to the Articles.
    The adoption of such resolutions shall be exempted from the majority requirement outlined in article 7.
	 	o) 	The
    determination of (i) the compensation strategy and of the principles, structure and design of compensation plans for the Executive
    Committee, (ii) the long-term incentive/equity plans, (iii) the compensation of the Directors and of the CEO to be presented
    to the shareholders, and of the terms of employment of the CEO, (iv) the Group and divisional financial, strategic and operational
    targets and the evaluation of target achievement.
	 	p)	The
    determination of the maximum aggregate amount or maximum partial amounts of compensation, in the event the General Meeting
    has not approved a proposal of the Board, as per the Articles.
	 	q) 	The
    determination of (i) whether or not a Director is independent, based on a proposal by the GNCRC, and (ii) whether or not the
    ACC Directors meet the financial literacy and expertise standards.
	 	r)	The
    decision on appropriate measures in case of a disclosure in accordance with article 4 of these Regulations.
	 	s)	The
    approval of other business, if such business exceeds the authority delegated from time to time by the Board to the Board Committees
    or to the Executive Committee.
	 	 	 
	 	 	Article
    13
	Delegation
                                         of Management

         
	 	Where
    not stipulated as a Board responsibility in the law, the Articles or these Regulations, the Board delegates the management
    of the Business to the Executive Committee, pursuant and subject to these Regulations.



 






     


    
	 7	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	 	 	Article
    14
	Meetings,
        Agenda

         
	 	The
        Board meets at the invitation of the Chairman as often as may be required.

         

        Invitations
        for Board meetings contain the meeting agenda and are sent out at least five business days in advance, except for urgent
        matters. Also, any Director may request a meeting for a specific purpose or the inclusion of a certain item on the agenda.

	 	 	 
	 	 	Article
    15
	Right
        to Request

        Information
	 	Directors
    have full and unrestricted access to the management and employees of the Group in the execution of their duties. 
	 	 	 
	 	 	Article
    16
	Independent
        Advisors

         
	 	The
    Board has the authority to retain independent advisors for any matters within the scope of its responsibilities.
	 	 	 
	 	 	Article
    17
	Evaluation
        of Board Performance

        
	 	The
    Board conducts an annual evaluation of the performance of the Board, of the Board Committees and of the Chairman.
	 	 	 
	 	 	Article
    18
	Board
        Committees

         
	 	The
    Board may establish ad hoc Board Committees and has the following permanent Board Committees:
	 	 	–	 Audit and Compliance Committee Compensation Committee
Governance, Nomination and Corporate Responsibilities Committee
	 	 	–	Risk Committee
and
	 	 	–	Science &
Technology Committee
	 	 	 
	 	 	The
    composition and duties of the permanent Board Committees are set forth in Appendix I.
	 	 	 
	 	 	Article
    19
	Chairman	 	In
    addition to other duties described in these Regulations and the Articles, the Chairman has the following duties:
	 	 	 
	 	 	a)	Provides
leadership to the Board in its governance role, coordinating the tasks within the Board.
	 	 	b)	Coordinates, together with the Chairpersons,
the work of the Board Committees.
	 	 	c)	Establishes
and keeps a close working relationship with the CEO, providing advice and support while respecting the fact that the day-to-day
management responsibility is delegated to the Executive Committee led by the CEO.
	 	 	d)	Promotes
effective relationships and communication between the Board, the CEO and the Executive Committee.
	 	 	e)	Takes the
lead in crisis situations.
	 	 	f)	Together
with the CEO, ensures effective communication with shareholders, other stakeholders and the general public; and
	 	 	g)	Works closely with the CEO in
evaluating Executives and in establishing succession plans for key management positions.



 






     


    
	 8	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	 	 	Article 20
	Vice-Chairman	 	In
    case and as long as the Chairman is incapacitated, the Vice-Chairman assumes all of the Chairman’s responsibilities.
	 	 	 
	 	 	If
    the Chairman is not independent, the Vice-Chairman will be tasked by the Board with the following duties:
	 	 	a)	Chairs the
sessions of the independent Directors; and
	 	 	b)	Leads the
independent Directors in case of a crisis or matter requiring their separate consideration or decision.
	 	 	 
	 	 	Every
    independent Director may request separate meetings of the independent Directors if the need arises.
	 	 	 
	Section
    5	 	Executive
    Committee
	 	 	 
	 	 	Article
    21
	CEO	 	In
    addition to other duties that may be assigned by the Board, the CEO, supported by the Executive Committee, has the following
    duties:
	 	 	 
	 	 	a)	Overall responsibility
for the management and performance of the Business.
	 	 	b)	Leads the
Executive Committee.
	 	 	c)	Builds and
maintains an effective Executive Committee and proposes adequate succession planning to the Board.
	 	 	d)	Represents Novartis, in coordination
with the Chairman, with major customers, financial analysts, investors and the media.
	 	 	 	 
	 	 	Article
    22
	Members
        of

        Executive
        Committee
	 	The
    Executive Committee is headed by the CEO. It consists of such members as appointed or removed by the Board.
	 	 	 
	 	 	Article
    23
	Duties
        of Executive

        Committee
	 	The
    Executive Committee is responsible for the management of the Business. In particular, and without limitation, the Executive
    Committee has the following duties:
	 	 	 
	 	 	a)	Regularly assess the achievement
of the targets for the Business.
	 	 	b)	Submit proposals to the Board or
to one of the Board Committees for approval for items, requiring such approval based on these Regulations or further internal
regulations.
	 	 	c)	Implement the decisions taken by
the Board or the Board Committees.



 






     


    
	 9	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	 	 	d)	Prepare and
submit quarterly and annual reports for the attention of the Board or the Board Committees, and keep the Board or the Board Committees
informed of all matters of fundamental significance to the Business and/or that are relevant to allow the Board or the Board Committees
to fully perform their duties.
	 	 	e)	Implement
modifications to the organization of the Business to ensure efficient operation of the Business and achievement of optimized consolidated
results.
	 	 	f)	Ensure appropriate
external stakeholder management, including an effective internal and external communication strategy.
	 	 	g)	Ensure that
management capacity, financial and other resources are provided and used efficiently.
	 	 	h)	Deal with such other matters as
are delegated by the Board or a Board Committee to the Executive Committee.
	 	 	 	 
	 	 	Article
    24
	Sub-committees
    of the Executive Committee	 	The
    Executive Committee may delegate duties as stipulated in article 23 above to other executives and committees and may
    empower them to further delegate their responsibilities and authorities. Each such delegation must be in writing, and clear
    responsibilities and accountabilities must be established. The CEO ensures proper reporting to the Executive Committee as
    needed.
	 	 	 
	Section
    6	 	Internal
    Audit
	 	 	 
	 	 	Article
    25
	Duties
    of Internal Audit	 	The
    Internal Audit has to:
	 	 	 
	 	 	a)	Carry out
operational and system audits, assisting the Divisions and Cross-Divisional Units in the accomplishment of objectives by providing
an independent approach to the evaluation, improvement, and effectiveness of their risk management and internal control framework.
All Divisions, Cross-Divisional Units and subsidiaries of the Group are subject to audit.
	 	 	b)	Prepare reports
regarding the audits it has performed, and report to the ACC and to the CEO material irregularities, whether actual or suspected,
without delay.
	 	 	c)	Perform such other functions and
audits as assigned to it by the Board, the ACC or the CEO.



 




     


    
	 10	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	Section
    7	 	Effectiveness,
    Amendments
	 	 	 
	 	 	Article
    26
	Effectiveness,
    Amendments	 	These
    Regulations come into effect on February 1, 2020 and replace former regulations of the Board, the Board Committees and the
    Executive Committee.
	 	 	 
	 	 	These
    Regulations may only be amended or replaced by the Board.



 


	 	 	 	 
	 	 	 	 
	 	 	Dr.
    Joerg Reinhardt 	Dr.
    Charlotte Pamer-Wieser
	 	 	Chairman
    	Corporate
    Secretary



 






     


    
	 11	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	Appendix
    I: 	 	Board
    Committees Charter	 
	Section
    1	 	General
    Provisions	12
	Section
    2	 	Roles
    and Responsibilities of the Board Committees	 
	 	 	-     
    Roles and Responsibilities of the ACC	13
	 	 	-     
    Roles and Responsibilities of the CC	16
	 	 	-     
    Roles and Responsibilities of GNCRC	19
	 	 	-     
    Roles and Responsibilities of RC	21
	 	 	-     
    Roles and Responsibilities of the STC	22



 






     


    
	 12	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	Section
    1	 	General
    Provisions
	 	 	 
	 	 	These
    General Provisions contain additional organizational requirements for Board Committees in addition to the rules set forth
    in the Regulations.
	 	 	 
	 	 	Article
    1
	Composition	 	The
        ACC, the GNCRC, the RC and the STC each consist of a minimum of 3 members. The CC consists of a minimum of 3 and a maximum
        of 5 members.

         

        The
        Board elects the Chairpersons of the Board Committees.

	 	 	 
	 	 	Article
    2
	Independence,

        Qualifications
	 	Each
    Director of the ACC, CC and GNCRC has to meet the independence criteria set forth in Appendix II.
	 	 	Each
    ACC member must further be financially literate, including at least one member who has accounting and related financial management
    expertise (“audit committee financial expert”), as such qualifications are interpreted by the Board in its business
    judgment.



 


	 	 	The
    “audit committee financial expert” must have
	 	 	(i) 	an understanding of generally accepted accounting
principles and financial statements;
	 	 	(ii)	the ability to assess the general application of
such principles in connection with the accounting for estimates, accruals and reserves;
	 	 	(iii)	experience preparing, auditing, analyzing or evaluating
financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the
breadth and complexity of issues that can reasonably be expected to be raised by the Group’s financial statements, or experience
actively supervising one or more persons engaged in such activities;
	 	 	(iv)	an understanding of internal control
over financial reporting; and
	 	 	(v)	an understanding of audit committee
functions.
	 	 	 	 
	 	 	Article
    3
	Coordination between
    ACC and RC	 	The
    Chairpersons of the RC and the ACC shall generally be appointed as members of the other Committee. To the extent appropriate,
    the Chairpersons of the ACC and the RC coordinate the work of the ACC and the RC, in particular to ensure that there are as
    few as possible overlaps.



 






     


    
	 13	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	 	 	Article
    4
	Meeting
    Participations and Interactions	 	Each
                                         Board Committee may invite to its meetings other Directors, Executives and such other
                                         persons, as the respective Board Committee deems appropriate to carry out its responsibilities.
                                         The Chairman may attend the Board Committee meetings in consultation with the relevant
                                         Chairperson.


 


Special
rules apply to the presence of the following persons at Board Committee meetings:









	 	 	(i)	An
    Executive shall not be present during the decision on his/her own pay at a CC meeting; or
	 	 	(ii)	Anyone
    with a personal interest in the matters to be discussed will be excluded from the ACC, GNCRC, RC and STC meeting, respectively.
	 	 	 	 
	 	 	Article
    5
	Advisors,

                                    Investigations
	 	The
    Board Committees shall have the authority to obtain advice and assistance from internal or external legal, accounting or other
    advisors. The ACC shall have the authority to conduct or authorize investigations into any matter within the scope of its
    responsibilities. 
	 	 	 	 
	 	 	Article
    6
	Debriefing
    to the Board	 	The
    Board Committees regularly report to the Board on its deliberations and decisions and on the items set forth in Section 2
    of this Appendix I. Other matters will be reported, as the Board Committees deem appropriate.
	 	 	 	 
	Section
2	 	Roles
    and Responsibilities of the Board Committees
	 	 	 	 
	 	 	Roles
    and Responsibilities of the Audit and Compliance Committee (ACC)
	 	 	 
	 	 	Article
    7
	ACC’s
    Mission Statement	 	The
    ACC assists the Board in monitoring the:
	 	 	(i)	integrity
    of the financial statements of the Group;
	 	 	(ii)	External
    Auditor’s qualifications and independence;
	 	 	(iii)	performance
    of the Internal Audit function and of the External Auditor; and
	 	 	(iv)	compliance
    by the Group with legal and regulatory requirements.
	 	 	 	 
	 	 	Article
    8
	ACC’s
    Role and Responsibilities	 	The
    ACC has the following roles and responsibilities:
	 	 	Regarding
    the External Auditor
	 	 	1.	Evaluate
    the qualifications, performance and independence of the External Auditor, including considering whether the External Auditor’s
    quality controls are adequate and whether the provision of permitted non-audit services is compatible with maintaining the
    External Auditor’s independence, taking into account the opinions of management and Internal Audit.


 






     


    
	 14	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 





	 	 	2.	 Ensure rotation of the audit partners of the External Auditor at least every five years. Consider whether, in order to ensure continuing auditor independence, it is appropriate to adopt a policy of rotating the external auditing firm on a regular basis. 
	 	 	3.	On behalf of the Board, which has fully delegated this task to the ACC, (1) select and nominate the External Auditor for election by the General Meeting, and (2) be directly responsible for the supervision and compensation of the External Auditor (including the resolution of any disagreement between management and the External Auditor regarding financial reporting). 
	 	 	4.	On behalf of the Board, which has fully delegated
this task to the ACC, pre-approve all auditing services, internal control-related services and non-audit services permitted under
applicable statutory law, regulations and listing requirements to be performed for the Group by its External Auditor.
	 	 	5.	Obtain and review a report from the External
Auditor at least annually regarding (1) the External Auditor’s internal quality- control procedures, (2) any material issues
raised by the most recent quality-control review, or peer review, of the firm, or by any inquiry or investigation by governmental
or professional authorities within the preceding five years respecting one or more independent audits carried out by the firm,
(3) any steps taken to deal with any such issues, and (4) all relationships between the External Auditor and the Group.
	 	 	6.	Discuss with the External Auditor the results
of their audits, any unusual items or disclosures contained in the audits and the matters required by Public Company Auditing
Oversight Board Auditing Standards No. 1301, as revised, and request a formal written statement from the External Auditor
documenting such discussion.
	 	 	Regarding Internal Audit
	 	 	7.	Review the significant reports to management,
prepared by the Internal Audit department and management’s responses and supervise the remediation of open audit issues.
	 	 	8.	Review periodically the adequacy of the organizational
structure, budget and appointment or replacement of the senior Internal Audit executives.
	 	 	9.	Discuss with the CEO, as needed, the Internal
Audit department’s responsibilities, staffing and any recommended changes in the planned scope of the Internal Audit.


 






     


    
	 15	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	 	 	Regarding
    Financial Reporting and internal controls
	 	 	10.	Review
    and discuss with management and the External Auditor the Company’s and Group’s quarterly and annual financial
    statements (including the sections on Operating and Financial Review and Prospects) to consider significant financial reporting
    issues and judgments made in connection with the preparation of the Company’s and Group’s financial statements,
    including any significant changes in the Company’s or Group’s selection or application of accounting principles.
	 	 	11.	On
        behalf of the Board, which has fully delegated this task to the ACC, approve the Company’s and Group’s quarterly
        financial statements for the first three quarters of each calendar year and the corresponding financial results releases.
        The Board remains responsible for the approval of the annual financial statements of the Company and the Group and of
        the corresponding financial results releases.

	 	 	12.	Review
    and discuss with management and the External Auditor their assessment of the effectiveness of the Group’s internal controls,
    disclosure controls and procedures for financial reporting and whether any changes are appropriate in light of such assessment.
	 	 	13.	Review
    and discuss (1) all significant deficiencies in the design or operation of internal controls which could adversely affect
    the Group’s ability to record, process, summarize and report financial data, including any material weaknesses in internal
    controls, (2) any fraud, whether or not material, that involves management or other employees who have a significant role
    in the Group’s internal controls, and (3) any significant changes in internal controls or in other factors that could
    significantly affect internal controls, including any corrective actions with regards to significant deficiencies and material
    weaknesses.
	 	 	14.	Review
    such other matters in relation to the Group’s accounting, auditing, financial reporting and compliance with law and
    internal policies.
	 	 	Regarding
    Significant Legal Matters and Regulatory Risks
	 	 	15.	Review
        major issues regarding the status of the Group’s material legal matters, as well as major legislative and regulatory
        developments that may have significant impact on the Group.

        

	 	 	Regarding
    an Effective Compliance Program
	 	 	16.	Review
    at least annually the processes and procedures used by management to execute an effective compliance program.
	 	 	17.	Review
        at least annually compliance by Novartis associates with those Group policies falling into the subject matter expertise
        of the ACC.




 






     


    
	 16	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	 	 	18.	Review
    updates from the Company’s SpeakUp office regarding whistleblowing activities and trends.
	 	 	19.	Establish
    procedures for (a) the receipt, retention and treatment of complaints received by the Group regarding accounting, internal
    accounting controls or auditing matters, and (b) the confidential, anonymous submission by employees of the Group of concerns
    regarding questionable accounting or auditing matters to the SpeakUp office.
	 	 	Other
	 	 	20.	Annually
    review the financial literacy of each ACC member to determine whether he/she meets the applicable legal standards, confirm
    the audit committee financial expert, and propose to the Board the appropriate determination and its disclosure.
	 	 	21.	Annually
    review and reassess the adequacy of Articles 7 - 8 of this Appendix I and submit proposed changes to the Board for approval.
	 	 	 	 
	 	 	Roles
    and Responsibilities of the Compensation Committee (CC)
	 	 	 	 
	 	 	Article
    9
	CC’s
    Mission Statement	 	The
    CC assists the Board concerning, but not limited to, the:
	 	 	(i)	compensation
    philosophy and strategy;
	 	 	(ii)	design
    of the compensation plans;
	 	 	(iii)	compensation
    of the Chairman, the Directors and of the CEO and other members of the Executive Committee. The CC has oversight of the remuneration
    policy for the wider employee population;
	 	 	(iv)	preparation
    of the Compensation Report and other relevant disclosures.
	 	 	 	 
	 	 	Pay
    for performance is one of the guiding principles of the compensation strategy of the Group. The Group aims to reward those
    associates who achieve competitive business results and exemplify the Group values and behaviors. The compensation strategy
    strives to strengthen the performance-oriented culture and to reinforce entrepreneurial behavior resulting in contributions
    that motivated and dedicated associates make to sustain superior business results whilst holding executives accountable for
    behavior that displays innovation, quality, performance, collaboration, courage and integrity.
	 	 	 	 
	 	 	Article
    10
	CC’s
    Role and Responsibilities	 	The
    CC has the following responsibilities:
	 	 	1.	Develop
    a compensation strategy in line with the principles described in the Articles, and submit to the Board for approval.



 






     


    
	 17	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	 	 	2.	Develop the principles and design of compensation plans, long-term incentive/equity plans, pension arrangements and benefits for
the Executives and the Directors, and submit to the Board for approval.

	 	 	3.	Support the Board in preparing the proposals to the General Meeting regarding the compensation of the Directors and the
        Executives.
	 	 	4.	Prepare the Compensation Report and submit to the Board for approval.
	 	 	5. 	Propose to the Board the contractual terms (if any) and compensation of the Directors (incl. the Chairman) and the CEO.
	 	 	6. 	Determine, after consulting with the CEO, the terms of employment, promotion or termination of the other Executives (except
    for the CEO).
	 	 	7. 	Develop the terms of, and administer, the Group’s long-term incentive/equity compensation plans, including the weightings,
    payout curves and caps for the chosen performance measures.
	 	 	8. 	Together with the RC, assess whether the Group’s incentives for associates below Executive Committee level are appropriately
    aligned to business performance and do not encourage excessive risk taking.
	 	 	9. 	Determine the critical performance measures (financial, strategic and operational) that inform how well the Group and its
    Divisions are performing in relation to the business strategy for incorporation into the incentive plans, as well as any measures
    relating to Environmental, Social and Governance (ESG).
	 	 	10. 	At the start of each performance period, review, after Board approval, the Group and divisional financial, strategic, operational
    and individual targets for Executive Committee members and direct reports to the Chairman. Incorporate these targets into
    the short-term and long-term incentive/equity compensation plans.
	 	 	11. 	Periodically review and propose to the Board for approval a peer group(s) of companies for executive compensation comparisons.
	 	 	12. 	At the start of each performance period, approve the target total direct compensation levels and the mix of compensation (fixed/variable,
    short/long-term, individual/Group/Division, and cash/equity) for Executive Committee members and direct reports to the Chairman
    taking into consideration pay and conditions for the wider population of Group associates.



 






     


    
	 18	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	 	 	13. 	At the end of each performance period, taking into consideration the Board’s evaluation of Group and divisional performance
    against targets established at the beginning of the performance cycle, approve performance results under the incentive plans,
    evaluate individual performance, approve the amount of compensation earned by Executive Committee members and recommend the
    amount of compensation earned by the CEO to the Board for approval taking into account the overall performance of the Business
    and, if appropriate, making adjustments to the formulaic outcome of any incentive plans, within the plan Rules.
	 	 	14. 	Consider and decide whether there is a need for malus and/or clawback provisions to be exercised and, if so, the extent and
    form of the malus and/or clawback.
	 	 	15. 	Incorporate the recommendations of the STC for the establishment of innovation targets under incentive compensation plans
    at the start of each performance cycle and measurement of achievement thereof at the end.
	 	 	16. 	Periodically assess the effectiveness of the executive short-term and long-term incentive plans in relation to the Group’s
    strategic objectives, values and pay-for-performance principles.
	 	 	17. 	Work together with other Board Committees, including the ACC, RC and the STC to ensure that executive compensation is correctly
    aligned to performance and is not structured in a way that could lead to inappropriate risk taking.
	 	 	18. 	Annually assess the level of Board compensation against the peer group and other relevant companies and submit to the Board
    its recommendations for the compensation of Directors and the compensation and terms of employment of the Chairman.
	 	 	19. 	Establish executive and director stock ownership guidelines and stock trading policies, and monitor compliance with such policies.

	 	 	20.	
        Inform the Board about policies, programs and key decisions as well as statistical comparisons and benchmarking of compensation
        levels against key competitors and regularly report to the Board on the decisions and deliberations of the Compensation
        Committee. 
	 	 	21.	In collaboration with the Chairman, oversee communication and engagement on executive compensation matters with shareholders
    and their advisors, including shareholder voting on Board and Executive Committee compensation, and assess the voting results
    on executive compensation matters of the most recent General Meeting.
	 	 	22. 	Be kept informed of the remuneration of the workforce and related policies and keep abreast of any developments. 

	 	 	23.	Annually assess the engagement and performance of compensation consultants or other outside advisors engaged by the CC
        and their independence in relation to any potential conflicts of interest.



 






     


    
	 19	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	 	 	24. 	Keep abreast of regulatory and corporate governance best practice requirements regarding Board, Executive Committee and other
    senior executive compensation.
	 	 	25.	Keep
abreast of market trends and consideration of external factors that may influence pay in terms of design, structure, quantum,
disclosure etc.

	 	 	26.	Establish an annual calendar of activities for the upcoming year, including special projects to be undertaken by the CC.
	 	 	27.	Review and reassess the adequacy of Articles 9 - 10 of this Appendix I and submit proposed changes to the Board for approval.
	 	 	28.	Assume other responsibilities assigned to it by law, the Articles and by the Board.
	 	 	 	 
	 	 	Roles and Responsibilities of the Governance, Nomination and Corporate Responsibilities Committee (GNCRC)
	 	 	 	 
	 	 	Article 11
	GNCRC’s
    Mission Statement	 	The GNCRC assists the Board in fulfilling its responsibilities with respect to the:



	 	 	(i)	governance of the Group;
	 	 	(ii)	identification of individuals who are qualified to become (or be re-elected as) Directors or the CEO; and
	 	 	(iii)	corporate and social responsibilities of the Group.
	 	 	 	 
	 	 	Article 12
	GNCRC’s
    Roles and Responsibilities	 	The GNCRC has the following roles and responsibilities:
	 	 	In General
	 	 	1.	Review periodically the Articles and the Regulations and recommend to the Board changes thereto in respect of good corporate
    governance and fostering shareholders’ rights.
	 	 	2. 	Consult with the Chairman in carrying out the duties of the GNCRC.
	 	 	3. 	Prepare and annually review succession plans for the Chairman, the Vice-Chairman, Directors, Board Committee members, Chairpersons
    and the CEO, and make proposals to the Board for the election and the re-election by the Board respectively by the AGM for
    the Directors, the Chairman and the CC Directors.
	 	 	4. 	Make proposals to the Board for the election of the Independent Proxy.
	 	 	5. 	Recommend such other actions not set out below regarding the governance of the Group that are in the best interests of the
    Group and the Company’s shareholders, as the GNCRC deems appropriate.



 






     


    
	 20	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	 	 	Board Composition
	 	 	6. 	Review the composition and size of the Board in order to ensure the Board has the proper expertise and consists of persons
    with sufficiently diverse backgrounds.
	 	 	7.	Determine the criteria for selection of the Chairman, Directors and Board Committee members. The GNCRC considers factors such
    as (i) personality, skills and knowledge, (ii) diversity of viewpoints, professional backgrounds and expertise, (iii) business
    and other experience relevant to the Business, (iv) the ability and willingness to commit adequate time and effort to Board
    and Board Committee responsibilities, (v) the extent to which personality, background, expertise, knowledge and experience
    will interact with other Directors to build an effective and complementary Board, and (vi) any disclosures made under article
    4 of the Regulations, in particular whether existing board memberships or other positions held by a candidate could lead to
    a Conflict of Interest.
	 	 	8.	With the participation of the Chairman, actively seek, interview and screen individuals qualified to become a candidate for
    the position as a Director, for recommendation to the Board.
	 	 	9. 	Assess and recommend to the Board as to whether Directors should stand for re-election. For its assessment, the GNCRC considers,
    among other things, age limit, contributions to the Board and the Company, and ability and willingness to commit adequate
    time to the Board and Board Committee matters.
	 	 	Board Committees
	 	 	10. 	With the Chairman, make recommendations to the Board for the creation of additional Board Committees or a change in mandate
    or dissolution of Board Committees.
	 	 	11. 	With the Chairman, periodically review the composition of the Board Committees. When doing so, the GNCRC takes into account
    whether a Board Committee member is suitable for the tasks of the respective Board Committee, including an envisioned quorum
    of independent Committee members, if applicable.
	 	 	12. 	With the Chairman, periodically review the chairmanships of the Board Committees.
	 	 	Conflicts, Other Directorships and Board member
	 	 	13. 	Review directorships and consulting agreements of Board members for conflicts of interest.
	 	 	14. 	Annually submit to the Board a proposal concerning the determination of the independence status of the Directors and the corresponding
    disclosure.
	 	 	Corporate Responsibilities of the Group
	 	 	15. 	Oversee the Group’s strategy and governance on corporate and social responsibility. 






 






     


    
	 21	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

  





	 	 	16.	Oversee
    key issues related to corporate and social responsibility that may affect the Business and the Group’s reputation.
	 	 	17.	Oversee
    the Company’s participation in the UN Global Compact.
	 	 	18.	Review
    and discuss emerging trends with regard to corporate responsibility.
	 	 	19.	Advise
    the Board and provide counsel to the management on corporate responsibility.
	 	 	20.	Approve
    the Novartis in Society Report.
	 	 	 	 
	 	 	Roles
    and Responsibilities of the Risk Committee (RC)


 





	 	 	Article
    13
	RC’s
    Mission Statement	 	The
    RC will assist the Board in ensuring that risks are properly assessed and professionally managed by:
	 	 	(i)	overseeing
    the Group’s risk management system and processes; and
	 	 	(ii)	reviewing
    the Group’s risk portfolio and related actions implemented by management.
	 	 	 
	 	 	Article
    14
	RC’s
    Role and Responsibilities	 	The
    RC has the following role and responsibilities:
	 	 	 
	 	 	1.	Ensure
    that the Group has implemented an appropriate and effective risk management system and process.
	 	 	2.	Ensure
    that all necessary steps are taken to foster a culture of risk-adjusted decision-making without constraining reasonable risk
    taking and innovation.
	 	 	3.	Together
    with the CC, assess whether the Group’s incentives for associates below Executive Committee level are appropriately
    aligned to business performance and do not encourage excessive risk taking.
	 	 	4.	Review
    with management and Internal Audit the identification, prioritization and management of the risks, the accountabilities and
    roles of the functions involved with risk management, the risk portfolio and the related actions implemented by management.
	 	 	5.	Inform
    the Board on a periodic basis on the risk management system and on the most significant risks and how these are managed.
	 	 	6.	Review
    such other matters in relation to the Group’s risk management, as the RC may, in its own discretion, deem desirable
    in connection with its responsibilities described above.
	 	 	7.	Keep
    itself up to date on risk management best practices. The Chief Ethics, Risk and Compliance Officer, or his/her designee, is
    expected to update the RC at least once a year on developments in this area.


  






     


    
	 22	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 


	 	 	Roles
    and Responsibilities of the Science & Technology Committee (STC)
	 	 	 
	 	 	Article
    15
	STC’s
    Mission Statement	 	The
    STC (i) oversees the science and technology strategy, including digital and data related innovation, (ii) evaluates and challenges
    the effectiveness and competitiveness of innovation-related functions, (iii) reviews and discusses emerging scientific trends
    and activities critical to the success of science and innovation, and (iv) reviews the R&D portfolio.
	 	 	 
	 	 	Article
    16
	STC’s
    Role and Responsibilities	 	The
    STC has the following role and responsibilities:
	 	 	1.	Monitoring
    emerging scientific, data-related, technological and research trends and issues, and bringing recommendations to the Board.
	 	 	2.	Informing
    the Board on a periodic basis about critical developments for the success of the portfolio and for scientific, technological
    and research activities as well as benchmarking.
	 	 	3.	Assisting
    the Board with setting the Company’s strategy for science, data, technology and research.
	 	 	4.	Assisting
    the Board with oversight and evaluation of the performance of the scientific, technological and research teams within the
    Company in relation to the strategy.
	 	 	5.	Review
    of performance and proposed targets in the area of science, technology and research.
	 	 	6.	Reviewing
    such other matters in relation to science, data, technology and research as the STC may, in its own discretion, deem desirable
    in connection with its responsibilities.


 






     


    
	 23	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 



	Appendix
    II	 	Independence
    Criteria for the Board and the Board Committees
	 	 	 
	 	 	Independence
    of the Directors
	 	 	The
    GNCRC annually submits to the full Board a proposal concerning the determination of the independent status of all Directors.
    For purposes of such assessment, the GNCRC considers all relevant facts and circumstances of which it is aware.
	 	 	 
	 	 	In
    order to be considered independent, a Director shall not have any material relationship with the Group other than his/her
    service as a Director.
	 	 	 
	 	 	I.
    Material Relationships
	 	 	1.	A
    Director will not be considered independent if
	 	 	–	The
    Director or his/her immediate Family Member owns more than 10% of the stock of the Company;
	 	 	–	The
    Director has received direct compensation (other than for former service as an interim Chairman ) of more than USD 120 000
    p.a. (other than dividends or Board/Board Committee fees and retirement or deferred pay for prior service, provided such compensation
    is not contingent in any way on continued service) from the Group within the last three years;
	 	 	–	A
    Family Member has received direct compensation of more than USD 120 000 p.a. (other than compensation received for service
    as an employee other than an executive officer) from the Group within the last three years;
	 	 	–	The
    Director is, or has been within the last three years, an employee of the Group;
	 	 	–	A
    Family Member is, or has been within the last three years, an executive officer of the Group;
	 	 	–	The
    Director is a current partner or employee of the External Auditor of the Group;
	 	 	–	A
    Family Member is a partner of the External Auditor or is an employee of the External Auditor and works on the Group’s
    audit;
	 	 	–	The
    Director or a Family Member is a former partner or employee of the External Auditor who personally worked on the Group’s
    audit during the last three years;
	 	 	–	The
    Director or a Family Member is, or has been within the last three years, employed as an executive officer of an enterprise
    while any of the present Executives serves or has served on that enterprise’s compensation committee;
	 	 	–	An
    enterprise has made payments to or received payments from the Group for goods, property or services in an amount that exceeds,
    in any of the last three fiscal years, the greater of USD 1 million or 2% of the enterprise’s consolidated
    gross revenues, and






	 	 	-  
    	The
    Director is a board member or employee of that enterprise or holds more than 10% of the shares in that enterprise; or
	 	 	-   
    	A
    Family Member is a board member or executive officer or holds more than 10% of the shares in that enterprise.



 






     


    
	 24	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

 



	 	 	2.	In
    addition to the independence criteria set forth above for all Directors in Section 1, an ACC Director will not be considered
    independent if 
	 	 	–	The
    ACC Director or his/her spouse, minor child, minor stepchild, or child or stepchild sharing the ACC Directors’ home,
    accepts any salary or consulting, advisory or other compensatory fee (other than Board/Board Committee compensation) from
    the Group;
	 	 	–	The
    ACC Director is a partner, a member, an officer such as a managing director, executive officer or occupies a similar position
    in an enterprise that provides advisory services such as accounting, legal, investment banking or financial advisory services
    to the Group;
	 	 	–	If
    an ACC Director simultaneously serves on the audit committees of more than two public companies other than the Company’s,
    then the GNCRC must determine that such simultaneous service would not impair the ability of such Director to effectively
    serve on the ACC.



 


		 	3.	In
                                         addition to the independence criteria set forth for all Directors in Section 1, above,
                                         when making its assessment as to the independent status of a CC Director, the GNCRC considers
                                         whether the CC Director receives compensation from any person or entity that would impair
                                         his or her ability to make independent judgments about the Executive compensation.



 


	 	II.
    Immaterial Relationships
	 	Unless
    the GNCRC concludes in its assessment to the contrary, a relationship is presumed not to impair the independence of a Director
    if



 


		 	–	The
                                         Director or a Family Member received from the Group, during the last fiscal year, personal
                                         benefits (other than the coverage of travel expenses incurred by a Family Member in connection
                                         with meetings of the Board) having an aggregate value of less than USD 5 000;
	 	 	–	A
                                         Family Member is an employee but not an executive officer of the Group, unless the Family
                                         Member is an ACC Director’s spouse, minor child, minor stepchild or child or stepchild
                                         sharing the ACC Director’s home;



 






     


    
	 25	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    

  





		–	The
                                         Director or a Family Member is a board member or executive officer of a non-profit organization
                                         and the Group’s contributions to such organization did not exceed, in any of the
                                         last three fiscal years, the greater of USD 1 million or 2% of the organization’s
                                         consolidated gross revenues;
		–	An
                                         enterprise in which the Director or a Family Member is a director, executive officer
                                         or employee has been indebted to the Group in connection with a transaction in the ordinary
                                         course of business or in an amount that did not exceed USD 100 000 during the last fiscal
                                         year;
		–	The
                                         Director or a Family Member serves on the board of another enterprise at which an Executive
                                         or another Director also serves as board member.



 


The
enumeration of relationships mentioned in this Section II is merely exemplary. The fact that a particular relationship is not
listed does not mean that the relationship affects the independence of a Director.


  



     


    
	 26	 	Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG




    




 


	 	 	Abbreviations
    and Definitions
	 	 	 
	ACC	 	Audit
    and Compliance Committee of the Board
	Appendix
    I 	 	Appendix
    I to these Regulations which forms an integral part of these Regulations (Board Committees Charter)
	Appendix
    II	 	Appendix
    II to these Regulations which forms an integral part of these Regulations (Independence Criteria for the Board and the Board
    Committees)
	Articles
    	 	Articles
    of Incorporation of the Company 
	Board
    	 	Board
    of directors of the Company 
	Board
    Committee(s)	 	Any
    or all committee(s) of the Board
	Business	 	Business
    operations conducted by the Group
	CC	 	Compensation
    Committee of the Board
	Chairman	 	Chairman
    of the Board 
	Chairperson(s)	 	Any
    or all Director(s) who chair(s) a / the Board Committee(s) 
	CO	 	Swiss
    Code of Obligations
	Cross-Divisional
    Unit(s)	 	Any
    or all cross-divisional organizational unit(s) supporting the Divisions 
	Company	 	Novartis
    AG
	Compensation
    Report	 	Compensation
    report of the Company
	Conflict
    of Interest	 	Any
    personal interest, or the interest of a closely related person or company, that a Director or Executive might have in a particular
    matter which does or might be regarded to conflict with the interests of the Company or the Group
	Director(s)	 	Any
    or all member(s) of the Board
	Division(s)	 	Any
    or all global operating divisions of the Group, including its business units, if any
	Executive(s)	 	Any
    or all Executive Committee member(s)
	Executive
    Committee	 	Executive
    committee of the Company
	External
    Auditor	 	The
    Group’s external auditor
	Family
    Member	 	An
    immediate family member of a Director, i.e., including a person’s spouse, parents, children, stepchildren, siblings,
    mother-, father-, brothers-, sisters-, sons- and daughters-in-law and anyone (other than domestic employees) who share such
    person’s home 
	General
    Meeting 	 	General
    meeting of shareholders of the Company
	GNCRC	 	Governance,
    Nomination and Corporate Responsibilities Committee of the Board
	Group	 	Novartis
    and its subsidiaries
	Independence
    Criteria	 	Independence
    criteria set forth in Appendix II 
	Internal
    Audit	 	The
    Group’s internal audit
	RC	 	Risk
    Committee of the Board
	Regulations	 	These
    Organizational Regulations of the Company, including Appendix I and Appendix II which form an integral part of these Regulations
	STC	 	Science
    & Technology Committee of the Board
	Vice-Chairman	 	Vice-Chairman
    of the Board